Legend Capital
VC Fund
Beijing, China
Legend Capital is a VC fund in Beijing focused on Health Care and Medical. Legend Capital, a subsidiary of Legend Holdings Ltd., started its vintage year in April, 2001 with a mission to become a top-notch and the most respected venture capital investment manager in China.Managing up to US$700 million across four funds, Legend Capital focuses on driving high-growth ventures with operations substantially based in Chinaor on markets related to China.Legend Capital mainly invests in early stage IT companies, specifically, in sectors of network applications and services, outsourcing and professional services, Infrastructure (IC design/key components), and mid-market growth stage companies in the fields of consumer goods, clean technology, health care, equipment manufacturing and modern services.Among over 60 portfolio companies are Joyo.com (acquired by Amazon.com), SinoCom (0299.HK), Solarfun Power (Nasdaq: SOLF), Spreadtrum Communications (Nasdaq: SPRD), China Sunshine Paper (2002.HK), and VanceInfo (NYSE:VIT), Eyang (0117.HK), etc.As an active investor, Legend Capital provides its portfolio companies extensive business resources and tailored services to assist with business development, company image building, and other critical company building activities on Chinese market so as to add value and maximize returns. Legend Capital is proud and thankful that it has the opportunity to blaze a trail with its innovative practice for China's venture capital industry.
- Total investments:
- 499
- Last investment:
- Lead investor:
- 42%
- Fund size:
- $177M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Legend Capital invests in
Stages Legend Capital invests in
Countries Legend Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 18 contacts → | |||
Round size
- Series A
- $2.4M–$93M
- Series B
- $12M–$107M
- Series C
- $15M–$200M
Investment Focus
Industry
- Health Care 63 (13%)
- Medical 51 (10%)
- Biotechnology 45 (9%)
- Manufacturing 32 (6%)
- Artificial Intelligence 29 (6%)
Stage
- Series B 106 (21%)
- Series A 73 (15%)
- Series C 64 (13%)
- Series D 22 (4%)
- Seed 19 (4%)
Country
- China 223 (45%)
- United States 19 (4%)
- South Korea 4 (1%)
- Japan 2 (0%)
- Singapore 2 (0%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Hongbin Zhou
Managing Director
|
Managing Director | Total investments: 4 | Find email | |
Jianqing Wang
Managing Director and Chief Management Advisor
|
Managing Director and Chief Management Advisor | Total investments: 1 | Find email | |
Joon Park
Co-CIO
|
Co-CIO | Total investments: 8 | Find email | |
Tony WANG
VP
|
VP | Total investments: 3 | Find email | |
Yi Kang
Director
|
Director | Total investments: 1 | Find email | |
| See all 18 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
NeuShen Therapeutics
|
NeuShen Therapeutics is a biotechnology company trailblazing the future treatment of neurological and psychiatric disorders. | $80M / Series B / Sep 03, 2026 | |
|
Shunyuan Technology
|
Shunyuan Technology is a high-tech enterprise specializing in the development of fusion simulators and advanced route design solutions, providing innovative technologies and intelligent systems for complex engineering, transportation, and industrial applications. | $1.5M / Seed / Aug 28, 2026 | |
Qingyan Technology
|
Qingyan Technology is an AI and data infrastructure firm specializing in world models and physical artificial intelligence. | Series A / Aug 19, 2026 | |
Navi Therapeutics
|
Navi Therapeutics is a biotechnology company focused on developing next-generation antibody-drug conjugates and antibody-based therapeutics for oncology | Series A / Aug 18, 2026 | |
Beyond Therapeutics
|
Beyond Therapeutics employs its ExCEED technology to speed the discovery and development of novel medications for unmet therapeutic needs. | $29.6M / Series A / Jul 30, 2026 | |
Liangyi Wanxiang
|
Liangyi Wanxiang is focuses on complete machines, product R&D, and technological innovation in atomic quantum computing. | Series A / Jul 19, 2026 | |
Mochi Intelligence
|
Mochi Intelligence is a high-tech enterprise specializing in the research and development of embodied intelligent robots. The company is committed to creating intelligent robots including humanoid robots that can truly understand and adapt to the real world through cutting-edge artificial intelligence technology and robotics. | $147.2M / Seed / Jul 06, 2026 | |
Qiuzhi Technology
|
Qiuzhi Technology focused on merging artificial intelligence and robotics, with an objective of bringing robots into households. | $100M / Angel / Jul 01, 2026 | |
Lingtai Krypton Biotechnology
|
Lingtai Krypton Biotechnology is an innovative corporation that specializes in the development of lncRNA drugs. | Series A / Jun 26, 2026 | |
|
Noitom Robotics
|
Noitom Robotics is an intelligent robot development company specializing in the sales, installation, and maintenance of industrial robots, as well as the sale of consumer robots and the research and development of intelligent robots. | Seed / Jun 16, 2026 | |
| See all 499 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Legend Capital invest in?
Legend Capital invests primarily in Health Care, Medical and Biotechnology startups, most often at Series B and Series A stage. Most of the 499 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Legend Capital's check size?
Legend Capital typically joins rounds of $2.4M–$93M at Series A, $12M–$107M at Series B and $15M–$200M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Legend Capital participates in.
How do I contact Legend Capital?
Public channels for Legend Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Legend Capital?
The team at Legend Capital includes Hongbin Zhou (Managing Director), Jianqing Wang (Managing Director and Chief Management Advisor) and Joon Park (Co-CIO), among 18 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
